Track topics on Twitter Track topics that are important to you
SAN RAMON, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs, today provided an update on recent corporate developments and announced financial results for the second quarter and six months ended June 30, 2015.
"I am pleased by the progress SteadyMed has made so far in 2015 and I am very optimistic about our future as we continue to execute our strategic plan. With regards to our lead drug product candidate Trevyent®, for the treatment of pulmonary arterial hypertension, or PAH, we have made significant advancements and have also entered into an exclusive license and supply agreement with Cardiome Pharma Corp. for Europe, Canada and the Middle East. In addition, we have completed our two-year program of human factors studies, which has validated the usability of Trevyent in the intended patient population," stated Jonathan Rigby, President and Chief Executive Officer of SteadyMed. "Many years of research and development are now coming to fruition and despite the recent need to implement some modifications relating to scale-up, we are now preparing to manufacture Trevyent, prior to the submission of our NDA."
Recent Corporate Developments
Second Quarter 2015 Financial Results
For the second quarter ended June 30, 2015, SteadyMed reported a net loss of $6.9 million, or $0.51 per share, compared to a net loss of $5.3 million, or $12.32 per share for the second quarter ended June 30, 2014. The current quarter's calculation of loss per share is based on 13,541,155 weighted-average shares outstanding, versus 501,828 outstanding shares in the prior-year period.
Total operating expenses for the second quarter ended June 30, 2015 were $6.8 million compared to $3.6 million for the quarter ended June 30, 2014, driven by an increase in research and development and general and administrative expenses.
Research and development (R&D) expenses for the second quarter of 2015 were $5.4 million, compared to $3.1 million for the second quarter of 2014. The increase in R&D expenses year-over-year was primarily due to the greater use of sub-contractor services for the Trevyent development and scale up program.
General and administrative (G&A) expenses were $1.1 million for the second quarter of 2015, compared to $0.3 million for the same period in 2014. The increase in G&A expenses was primarily due to increased salaries and related expenses, and additional financial consulting, investor relations and legal services in support of operating as a public company.
Cash and cash equivalents were $43.1 million as of June 30, 2015. Management believes that the company has sufficient liquidity for at least the next 12 months.
Conference Call and Webcast
SteadyMed's management will host a webcast and conference call regarding this announcement at 4:30 p.m. EDT today. The live call may be accessed by dialing (866) 430-0928 for domestic callers and (704) 908-0411 for international callers and referring to the conference number 94750929. A live webcast of the call will be available from the investor relations sections of the company website at www.steadymed.com, and will be archived there for 30 days. A telephone replay of the call will be available by dialing (855) 859-2056 for domestic callers, or (404) 537-3406 for international callers, and entering the conference number 94750929.
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. In June 2015, SteadyMed signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning the company's ability to advance its development-stage product candidates, including Trevyent. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q filed on August 13, 2015. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.
|STEADYMED LTD. AND ITS SUBSIDIARIES|
|CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS|
|(in thousands, except share and per share data)|
|Three months ended||Six months ended|
|June 30,||June 30,|
|Research and development||$5,429||$3,101||$9,838||$5,352|
|General and administrative||1,111||286||2016||649|
|Total operating loss||6,825||3,627||12,361||6,460|
|Financial expenses (income), net||92||1,674||(11)||1,593|
|Loss before taxes on income||6,917||5,301||12,350||8,053|
|Taxes on income||8||36||131||81|
|Net loss per share:|
|Basic and diluted net loss per Ordinary Share||$0.51||$12.32||$1.78||$19.06|
|Weighted-average number of Ordinary Shares used to compute basic and diluted net loss per share||13,541,155||501,828||7,555,684||501,828|
|STEADYMED LTD. AND ITS SUBSIDIARIES|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|(U.S. dollars in thousands, except share and per share data)|
|June 30,||December 31,|
|Cash and cash equivalents||$43,145||$6,167|
|Liabilities and shareholders' equity (deficit):|
|Liabilities||$ 5,607||$ 10,978|
|Convertible preferred shares||--||35,669|
|Shareholders' equity (deficit)||40,668||(36,321)|
|Total liabilities, convertible preferred shares & shareholder's equity (deficit)||$46,275||$10,326|
CONTACT: Marylyn Rigby Director of Marketing and Investor Relations 925-272-4999 firstname.lastname@example.org Robert H. Uhl Managing Director Westwicke Partners 858-356-5932 email@example.comNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...